SSAs for pancreatic neuroendocrine tumours – ENETS 2020 Poster #1
SSAs for pancreatic neuroendocrine tumours – ENETS 2020 Poster #1
Dr. Teresa Alonso Gordoa, Asst. Prof. Mauro Cives, Dr. Faidon Laskaratos, Dr. Elettra Merola, Dr. Angela Lamarca, Dr. Rachel van Leeuwaarde, Asst. Prof. Louis de Mestier, Dr. Jorge Hernando, Dr. Panpan Zhang
Dr Teresa Alonso Gordoa provides a summary of the poster presented at the ENETS 2020 conference: SSAs for pancreatic neuroendocrine tumours: is there any benefit when Ki-67 is ≥10%?
Dr. Teresa Alonso Gordoa
Medical Oncologist
Hospital Universitario Ramón y Cajal
Spain

Asst. Prof. Mauro Cives
Medical Oncologist
University of Bari
Italy

Dr. Faidon Laskaratos
Gastroenterologist
Royal Free Hospital
United Kingdom (UK)

Dr. Elettra Merola
Gastroenterologist
Santa Chiara Hosptial
Italy

Dr. Angela Lamarca
Medical Oncologist
The Christie NHS Foundation Trust
United Kingdom (UK)

Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands

Asst. Prof. Louis de Mestier
Gastroenterologist
Beaujon University Hosptial
France

Dr. Jorge Hernando
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain

Dr. Panpan Zhang
Medical Oncologist
Peking University Cancer Hospital & Institute
China
Dr. Teresa Alonso Gordoa
Medical Oncologist
Hospital Universitario Ramón y Cajal
Spain
Dr. Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.
Dr. Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bayer, BMS, Eusa Pharma, Novartis, Roche, Sanofi Genzyme, Ipsen and Pfizer.
Asst. Prof. Mauro Cives
Medical Oncologist
University of Bari
Italy
Dr. Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr. Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr. Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr. Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr. Cives is co-author of over 30 peer-reviewed papers.
Asst. Prof. Mauro Cives has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA and Ipsen.
Dr. Faidon Laskaratos
Gastroenterologist
Royal Free Hospital
United Kingdom (UK)
Dr. Faidon Laskaratos has no relevant financial relationships to disclose.

Dr. Elettra Merola
Gastroenterologist
Santa Chiara Hosptial
Italy
Dr. Angela Lamarca
Medical Oncologist
The Christie NHS Foundation Trust
United Kingdom (UK)
Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.
Dr. Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED.
Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands
Dr. Rachel van Leeuwaarde has no relevant financial relationships to disclose.
Asst. Prof. Louis de Mestier
Gastroenterologist
Beaujon University Hosptial
France
Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.
Asst. Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Novartis, Pfizer, Ipsen.
Dr. Jorge Hernando
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Spain
Dr. Jorge Hernando has no relevant financial relationships to disclose.
Dr. Panpan Zhang
Medical Oncologist
Peking University Cancer Hospital & Institute
China
Dr. Panpan Zhang has no relevant financial relationships to disclose.
|
5 min
|
Apr 2020
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.